Clinical Trial Update: Evaluate Harm Reduction Products as a Second Line Intervention for Adult Smokers Who Do Not Quit With NRT [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating harm reduction products as a second-line option for adults who do not quit with nicotine replacement therapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tobacco Use Disorder

Snippet

Sponsor: Rose Research Center, LLC | Conditions: Smoking Cessation, Harm Reduction | Phase 3 | Status: TERMINATED